Table 1.

Univariate analysis of demographic and clinical features and chemotherapeutic agents that represent factors predictive of the occurrence of sinusoidal obstruction syndrome (SOS)

	Group 1	Group 2	Group 3	Group 4	P-value
	(SOS grade 0, n = 35)	(SOS grade 1, n = 49)	(SOS grade 2, n = 51)	(SOS grade 3, n = 16)
Age, years, mean (range)	64 (27–75)	65 (14–82)	65 (47–86)	64 (40–73)	0.130
Gender, male/female, n	21/14	19/30	26/25	9/7	0.890
Portal vein embolization, n (%)	9 (26%)	20 (41%)	20 (39%)	7 (44%)	0.200
Splenomegaly (>13 cm), n (%)	0	0	2 (4%)	2 (13%)	0.009
Chemotherapy, n (%)	24 (69%)	45 (92%)	46 (90%)	15 (94%)	0.007
FOLFOX, patients, n (%)	11 (31%)	28 (57%)	29 (57%)	9 (56%)	0.005
Number of cycles, mean (range)	6 (3–12)	8 (3–21)	9 (2–18)	7 (4–24)	0.210
Interval between chemotherapy and surgery, months, mean (range)	1 (1–6)	2 (1–6)	1 (1–6)	1 (1–5)	0.180
FOLFIRI, patients, n (%)	13 (37%)	20 (41%)	15 (29%)	5 (31%)	0.410
Number of cycles, mean (range)	7 (4–35)	6 (2–26)	8 (2–36)	8 (3–20)	0.520
Interval between chemotherapy and surgery, months, mean (range)	1 (1–5)	1 (1–5)	2 (1–6)	1 (1–6)	0.13
Bevacizumab, patients, n (%)	9 (26%)	8 (16%)	3 (6%)	0	0.005 (protective effect)
Number of cycles, mean (range)	10 (4–16)	8 (6–12)	7 (6–10)	–	0.220
Interval between chemotherapy and surgery, months, mean (range)	2 (1–6)	2 (1–3)	3 (2–4)	–	0.800
Cetuximab, patients, n (%)	4 (11%)	8 (16%)	5 (10%)	1 (6%)	0.470
Number of cycles, mean (range)	12 (6–18)	6 (2–26)	8 (4–36)	20	0.340
Interval between chemotherapy and surgery, months, mean (range)	2 (1–2)	1 (1–6)	1 (1–2)	1	0.240
5-Fluorouracil, patients, n (%)	0	0	3 (6%)	4 (25%)	<0.001
Number of cycles, mean (range)	NA	NA	8 (6–12)	7 (2–12)	0.480
Interval between chemotherapy and surgery, months, mean (range)	NA	NA	1 (1–2)	1 (1–2)	0.180

PVE, portal vein embolization

5-FU, 5-fluorouracil

FOLFOX, folinic acid, 5-FU, oxaliplatin

FOLFIRI, folinic acid, 5-FU, irinotecan

NA, not available.